Officials warn rising drug resistance could undo decades of progress in controlling HIV, hepatitis, and sexually transmitted infections.
Data from a new surveillance report show rising resistance to ceftriaxone and cefixime, the two antibiotics currently recommended for gonorrhea treatment.
High-level tetracycline resistance and reduced susceptibility to cefixime was found in gonorrhea bacteria from doxyPEP users.
Reported cases of chlamydia, gonorrhea, and syphilis declined for the third straight year in 2024, but cases of newborn syphilis were up by 2%.
The results of a randomized controlled trial show a single dose of benzathine penicillin G is noninferior to 3 doses for treating early syphilis.
The UK's National Health Service is offering the 4CMenB vaccine, which provides cross-protection against gonorrhea, to patients at the greatest risk of infection.
Researchers in Italy observed a significant reduction in antibiotic use for sexually transmitted infections after the targeted introduction of doxyPEP.
Fifty-one babies were born with congenital chlamydia, and 23 were born with congenital syphilis.
A genomic analysis finds the percentage of US gonorrhea isolates carrying tetracycline resistance genes rose from 10% in 2020 to more than 30% in 2024.
Doxycycline post-exposure prophylaxis isn't formally available in the Netherlands, but 23% of respondents to an online survey said they've used it.
